1-14-05

BEST AVAILABLE COPY

PCT/GB 00/03424

10/069242

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 18 OCT 2000
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed R. Mahoney

Dated 2 October 2000

Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE
A
25 NOV 1999
RECEIVED BY FAX

The Patent Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference — P230641/PKE/BOU

2. Patent application number (The Patent Office will fill in this part) — 9927802.0 — 25 NOV 1999

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Giltech Limited
9/12 North Harbour Estate
AYR
KA8 8AA

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation — United Kingdom

4. Title of the invention — "Growth Substrate"

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Murgitroyd & Company
373 Scotland Street
GLASGOW
G5 8QA

Patents ADP number (if you know it) — 1198013

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
-		

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-	

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

A
25 NOV 1999
RECEIVED BY FAX

Continuation sheets of this form	
Description	23
Claim(s)	–
Abstract	–
Drawing(s)	6

10. If you are also filing any of the following, state how many against each item.

Priority documents	–
Translations of priority documents	–
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	–
Request for preliminary examination and search *(Patents Form 9/77)*	–
Request for substantive examination *(Patents Form 10/77)*	–
Any other documents *(please specify)*	–

11. I/We request the grant of a patent on the basis of this application.

Signature Murgitroyd & Co Date 25.11.1999

MURGITROYD & COMPANY

12. Name and daytime telephone number of person to contact in the United Kingdom Beverley Ouzman 0141 307 8400

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

GROWTH SUBSTRATE

The present invention provides a growth substrate for cell culture. In particular, the present invention provides a cell culture growth substrate for tissue engineering.

Tissue engineering is expected to transform orthopaedics treatments, cancer therapy and the treatment of chronic degenerative diseases. Tissue engineering concerns the provision of a graft comprising living cells or suitable substrate to sustain the growth of such cells which integrate into the patient providing expedited wound healing and repair or an alternative drug delivery or gene therapy delivery system. The tissue engineering graft may be an autograft, allograft or xenograft. Autografts are formed with the patient's own cells, cultured with a suitable growth medium or substrate. Allografts rely upon cells donated from an alternative same species source (including cadaver or foetal sources) whilst xenografts rely upon cells donated from other species. Both allografts and xenografts may be treated to

minimise autoimmune rejection of the graft following implantation.

There are numerous potential applications for tissue engineered grafts, including reconstructive surgery, orthopaedics or dental applications, burn treatments or ulcer treatments (including venous ulcers and diabetic foot ulcers). A number of tissue engineered grafts have been described in the literature (see Dutton, "Tissue Engineering", Genetic Engineering News, Vol 18, No 8, April 15, 1998).

Examples of such tissue engineered grafts include APLIGRAF (Trade Mark) which is a bilayer graft including both differentiated keratinocytes and a layer of fibroblasts in a collagen matrix. APLIGRAF has been used as a skin graft, particularly for burns, diabetic foot ulcers, excisional surgery and venous ulcers (Bender, "Healing of Difficult to Heal Wounds Using a Bilayered Skin Construct", 11th Annual Symposium on Critical Issues in Surgery-Wound Healing, Science and Technology, 3-5 December 1998, St Thomas, US Virgin Islands). Other bioengineering skin equivalents include INTEGRA (Trade Mark), a xenograft of bovine collagen, glycosaminoglycans (GAG) and silastic sheet; ALLODERM (Trade Mark), an allograft of treated cadaver skin; and DERMOGRAFT (Trade Mark), an allograft of neonatal fibroblasts on a polyglactin scaffold. Tissue engineered grafts for bone include RAINBOW (Trade Mark) of IsoTis BV which is a biomimetic coating which allows a bone-like layer to grow over metal prosthesis and serves as a scaffold

for bone growth, and also EMBARC (Trade Mark) which is a resorbable bone repair material.

Despite the numerous tissue engineering grafts currently being developed, there is still a demand for further and improved products. We have now found that water-soluble glass acts as a support or matrix for cell growth and hence the glass has utility in tissue engineering.

The present invention thus provides a cell culture growth substrate comprising a water-soluble glass matrix adapted to sustain the growth of living cells. Preferably the substrate will comprise or have at least a portion of the surface thereof coated with living cells.

In one embodiment the cell culture growth substrate is pre-seeded with living cells and hence the matrix comprises or has at least a portion of its surface coated with living cells.

In one embodiment, the cell culture growth substrate will be useful as a tissue graft, i.e. is designed for implantation into a patient to replace or promote repair of damaged tissues.

The water-soluble glass matrix will of course be biocompatible. Generally, the biodegradation of the water-soluble glass following implantation of the graft into a patient will be pre-determined to be

compatible with the timescale required for regrowth of the tissues concerned.

The glass present in the graft acts as a cell support matrix and will function as such in vivo. Thus the graft can be used directly in vivo to provide a temporary biodegradable scaffold which will encourage ingrowth of surrounding tissues. In other embodiments pre-seeding of the graft with a pre-selected cell type, and optionally growth of that cell type, prior to implantation may be desirable.

In an alternative embodiment, the cell culture growth substrate is intended for non-clinical purposes, for example in bio-reactor and fermentation technologies for the production of drugs and other biologically derived chemicals. Organisms usually grow with increased confluence on surfaces, and enzyme reactions (and many other biochemical reactions) are generally most efficient when the enzyme is bound to a reaction surface. Beads, sinters and fibres can be used to provide the required mechanical support, with large (productive) surface areas and additional features such as controlled inorganic micro-nutrient supply, contamination control, pH buffering and a biocompatible carrier which will allow the subsequent transfer or filtration of cells, enzymes or other components bound to its surface on completion of the reaction stage.

Conveniently the water-soluble glass matrix may be in the form of water-soluble glass fibres and reference

is made to our WO-A-98/54104 which describes the production of suitable glass fibres. Whilst the glass fibres can be used in the form of individual strands, woven (e.g. a 1 x 1 basket weave) or non-woven mats may also be produced from the fibres and used as the matrix. The individual fibres of a non-woven mat may be gently sintered together to obtain coherence of the strands. Alternatively, the fibres may be used as glass wool and this form of matrix is especially suitable where the graft requires a 3D shape.

Alternatively, the water-soluble glass matrix may be produced from finely comminuted glass particles (for example having an average diameter of from 50 μm to 6 mm). Optionally, the glass particles may be sintered together to form a porous structure into or onto which cells may be seeded and in this embodiment the glass particles will have a preferred diameter of from 53 μm to 2 mm, preferably 400 μm to 2 mm. Again, a three-dimensionally shaped graft may be produced (if necessary individually tailored to be compatible with the wound site of the patient) from the sinter. Alternatively, particles following a Fuller curve packing distribution and having a range of diameters of 0.3 mm to 5.6 mm may be used.

In a further embodiment the glass may simply be in the form of a glass sheet, which may be substantially planar or may be contoured to a required shape. Etched, ground or patterned glass sheet may be used in addition to plain surfaced glass.

The water-soluble glass preferably includes phosphorous pentoxide (P_2O_5) as the glass former.

Generally the mole percentage of phosphorous pentoxide in the glass composition is less than 85%, preferably less than 60% and especially between 30-60%.

Alkali metals, alkaline earth metals and lanthanoid oxides or carbonates are preferably used as glass modifiers.

Generally, the mole percentage of alkali metals, alkaline earth metals and lanthanoid oxides or carbonates is less than 60%, preferably between 40-60%.

Boron containing compounds (e.g. B_2O_3) are preferably used as glass additives.

Generally, the mole percentage of boron containing compounds is less than 15% or less, preferably less than 5%.

Other compounds may also be added to the glass to modify its properties, for example SiO_2, Al_2O_3, SO_3, sulphate ions (SO_4^{2-}) or transition metal compounds (e.g. first row transition metal compounds).

Typically the soluble glasses used in this invention comprise phosphorus pentoxide (P_2O_5) as the principal glass-former, together with any one or more glass-modifying non-toxic materials such as sodium

oxide (Na_2O), potassium oxide (K_2O), magnesium oxide (MgO), zinc oxide (ZnO) and calcium oxide (CaO). The rate at which the glass dissolves in fluids is determined by the glass composition, generally by the ratio of glass-modifier to glass-former and by the relative proportions of the glass-modifiers in the glass. By suitable adjustment of the glass composition, the dissolution rates in water at 38°C ranging from substantially zero to 25mg/cm^2/hour or more can be designed. However, the most desirable dissolution rate R of the glass is between 0.001 and 2.0mg/cm^2/hour.

The water-soluble glass is preferably a phosphate glass, and preferably comprises a source of metal ions which confer either antimicrobial protection or enhanced cell growth, or both, or which are useful trace elements. Examples include silver, copper, magnesium, zinc, iron, cobalt, molybdenum, chromium, manganese, cerium, selenium, and these metal ions can be included singly or in any combination with each other. Where silver ions are of interest, these may advantageously be introduced during manufacture as silver orthophosphate (Ag_3PO_4). The glass preferably enables controlled release of metal ions and other constituents in the glass and the content of these additives can vary in accordance with conditions of use and desired rates of release, the content of silver generally being up to 5 mole %. While we are following convention in describing the composition of the glass in terms of the mole % of oxides, of halides and of sulphate ions, this is not intended to imply

that such chemical species are present in the glass nor that they are used for the batch for the preparation of the glass.

The optimum rate of release of metal ions into an aqueous environment may be selected by circumstances and particularly by the specific function of the released metal ions. The invention provides a means of delivering metal ions to an aqueous medium at a rate which will maintain a concentration of metal ions in said aqueous medium of not less than 0.01 parts per million and not greater than 10 parts per million. In some cases, the required rate of release may be such that all of the metal added to the system is released in a short period of hours or days and in other applications it may be that the total metal be released slowly at a substantially uniform rate over a period extending to months or even years. In particular cases there may be additional requirements, for example it may be desirable that no residue remains after the source of the metal ions is exhausted or, in other cases, where the metal is made available it will be desirable that any materials, other than the metal ions itself, which are simultaneously released should be physiologically harmless. In yet other cases, it may be necessary to ensure that the pH of the resulting solution does not fall outside defined limits.

Generally, the mole percentage of these additives in the glass is less than 25%, preferably less than 10%.

The cells may be any suitable cells required for grafts. Particular mention may be made of keratinocytes, fibroblasts, chrondrocytes and the like as preferred cell types. Mention may also be made of stem cells (mesenchymal, haematopoetic, and embryonic), Schwaan cells, keratinocytes (epithelial cells), chondrocytes, osteoblasts, endothelial cells and other fibroblasts, cardiac cells (and other myoblasts), pancreatic β cells and periodontal tissues e.g. Dentine, but the invention is not limited to these cell types alone.

Embodiments of the invention will be described with reference to the following non-limiting examples and Figures in which:

Fig. 1 Chondrocytes forming a monolayer on a glass fibre (Example 1) as viewed by laser scanning confocal microscope.

Fig. 2 Fluorescent microscopy of HUE cells on MATT01 glass fibres (see Example 2).

Fig. 3 Fluorescent microscopy of HUE cells on MATT04 glass fibres (see Example 2).

Fig. 4 SEM picture of L929 cells on glass surface at x30 magnification (see Example 3).

Fig. 5 SEM picture of L929 cells on glass surface at x170 magnification (see Example 3).

Fig. 6 SEM picture of L929 cells on glass surface at x215 magnification (see Example 3).

Fig. 7 SEM picture of L929 cells on glass surface at x610 magnification (see Example 3).

Example 1

Introduction

Controlled Release Glass (CRG) is a phosphate-based material which degrades at a predeterminable rate. The potential for using CRG as a cartilage engineering matrix has been assessed using isolated equine chondrocytes with *in-vitro* techniques. The glass was provided in fibrous form in three different compositions. The three CRG compositions provided have showed potential as a tissue engineering substrate.

Materials and Method

A total of 200,000 chondrocytes isolated from horse articular cartilage were added to each 2 cm well in a 24 well plate. Every well contained 0.02 grams of glass fibre sample. Four different fibres F1 to F4 (diameters 20-30 μm) were analysed: F1 - containing Fe_2O_3 and NaF, F2 - containing Ce_2O_3 and Se. The composition of glasses used to form F1 to F4 are set out below in Table 1. The culture medium (containing 10% FCS) was changed daily. At time periods of 3 days, 1 week and 2 weeks, the samples were stained using rhodamine phalloidin and oregan green for the viewing of actin and tubulin using a laser scanning confocal microscope. At the same time periods, the cell supernatant was removed and stored at -80°C until analysis on cell viability and type II collagen production could be performed. Production of type II

collagen was analysed by using RT-PCR analysis on the cDNA from the chondrocyte population in contact with the glass fibres. The total RNA was prepared from the cell population by the addition of 1 ml of TRIzol (SIGMA) to the cell population for 5 minutes. After this time, the TRIzol was retrieved and stored at -80°C until RT-PCR analysis could be carried out. The RT-PCR analysis was performed by tagging with primers for collagen type II and with gapDH for cell viability.

Zymography was also performed at time periods of 4 days, 1 week and 2 weeks for detection of matrix metalloproteinases (MMP's) produced by the chondrocytes.

Table 1

BATCH RECORD SELECTION

Code	Formulation as mole%													Solution Rates		Physical Form
	Na_2O	CaO	Ag_2O	P_2O_5	MgO	K_2O	B_2O_3	MnO	Fe_2O_3	NaF	Ce_2O_3	Se	TOTAL	Annealed @ 37.5°C ($mg.cm^{-2}.hr^{-1}$)	Non-Annealed @ 37.5°C ($mg.cm^{-2}.hr^{-1}$)	
F1	25.35	17.26		46.78			5.75	1.5	1.76	1.1			100	N/A	N/A	F,C + R
F2	25.78	17.42		46.1			5.82	1.52	0.95		2.01		99.6	N/A	N/A	F,C + R
F3	25.19	17.03		45.05			5.68	1.49	0.93	0.4	1.96	2.27	100	N/A	N/A	F,R + C
F4	32		3	46	4	10	5						100	0.331	0.9614	F + R

F=fibres; C=cullet; R=rods

IT BY:MURGITROYD, GLASGOW ;25-11-99 ;11:49AM ; MURGITROYD & CO.→ 01633 814444;#17

Results and Conclusions

Chondrocytes adhered to all three types of fibre sample. At the 3 day time period, the cells appeared to be rounded. At 1 week and 2 weeks, confocal microscopy indicated cell proliferation between all time periods. At 1 week and 2 weeks, the cells were elongated and formed a monolayer along the fibre length as can be seen in Figure 1.

The RT-PCR analysis showed that fibres F2 and F3 were producing collagen type II up to and including the two week time period indicating that the cells retained their chondrocytic phenotype.

The zymography performed on F2 and F3 showed that the cells in contact with these fibres produced MMP2 at all three time periods, but in a greater quantity at 2 weeks than 1 week, and at 1 week than 4 days. This increase of MMP2 production is expected, as the cells were seen to have increased in number at these time periods from the confocal microscope analysis.

In conclusion, all three fibres types showed cell adherence and the chondrocytes adhered to F2 and F3 appear to retain the ability to produce type II collagen.

Example 2

Biological Evaluation of Non-woven Mat Fibres

1. Objective

Using in-vitro techniques determine:

a. The cytotoxicity of a series of five non-woven mat CRG fibres.

b. The potential of the fibres as a cell substrate matrix.

2. Scope

The test procedures apply to all fibre samples.

3. Equipment and Materials

3.1 Equipment

3.1.1 Laminar air flow hood

3.1.2 Incubator maintained at 37°C/5% carbon dioxide

3.1.3 Refrigerator at 4°C

3.1.4 Freezer at -18°C

3.1.5 Vacuum source

3.1.6 Phase contrast microscope

3.2 Materials

3.2.1 Sterile plastic-ware pipettes

3.2.2 Sterile glass pipettes

3.2.3 24 well Sterile dishes

3.2.4 Surgical grade forceps

3.2.5 Surgical grade scissors

3.2.6 Sterile Universal containers

3.2.7 L929 cell culture line (ATCC NCTC Clone 929)

3.2.8 Human Umbilical endothelial cells (primary cell source, Liverpool Women's Hospital)

3.2.9 TCPS negative control

3.2.10 CRG fibres:

D021298F1 (MATT01)

D301198F1 (MATT02)

D100299F1 (MATT03)

D161298F2 (MATT04)

D171298F2 (MATT05)

All CRG fibres were supplied non-sterile in quantities 8g-38g. The compositions of CRG fibres used (MATT01 to 05) are set out below in Table 2.

Table 2

BATCH RECORD SELECTION

Code	Formulation as Mole%													Solution Rates		Physical Form
	Na_2O	CaO	Ag_2O	P_2O_5	MgO	K_2O	B_2O_3	MnO	Fe_2O_3	NaF	Ce_2O_3	Se	TOTAL	Annealed @ 37.5°C ($mg.cm^{-2}.hr^{-1}$)	Non-Annealed @ 37.5°C ($mg.cm^{-2}.hr^{-1}$)	
MATT01		27.98		46.56	19.07		6.36						99.97	N/A	N/A	R,F + C
MATT02		30		50	20								100	N/A	N/A	F,R + C
MATT03		25		50	20	5							100	0.0095	0.0151	R + F
MATT04	26.05	17.6		47.04			5.88	1.54	0.96	0.4	1		100.47	0.0143	0.0165	R + F
MATT05	25.19	17.03		45.05			5.68	1.49	0.93	0.4	1.96	2.27	100	0.0177	0.02	R + F

R=rods; F=fibres; C=cullet

T BY:MURGITROYD, GLASGOW ;25-11-99 ;11:50AM ; MURGITROYD & CO.→ 01633 814444;#21

4. Procedure

4.1 Test sample preparation

4.1.1 Test samples were cut to the appropriate size (see section 4.2.1).

4.1.2 Tissue culture polystyrene was employed as a negative control. The controls were not in the same physical form as the test material.

4.2 Fibres were examined in contact with the L929 cell line before any cleaning procedure. Fibres were examined in contact with both cell lines after cleaning in acetone, washing in PBS and sterilising in a dry oven at 190°C for 2 hours.

4.3 Cell preparation

4.3.1 A cell subculture was prepared 24 hours before being introduced to the fibres.

4.4 Test procedure

4.4.1 A small "bed" of the fibres was placed in the bottom of each well.

4.4.2 The cell/medium preparation was gently pipetted onto the fibre bed.

4.4.3 The 24-well plates were incubated and examined at 24 hours and 48 hours.

4.5 Interpretation of results

4.5.1 At the conclusion of the incubation period the plates are removed from the incubator and examined under phase contract microscopy using x10 and x20 objective lenses.

4.5.2 Each test and control material was initially evaluated using the scoring system detailed below. This evaluation was based on the appearance of the cells which were attached to the TCPS surface. It was not possible to carry out such an evaluation on the cells adhering to the fibres.

Table 3 : Reactivity Responses

Grade	Reactivity	Conditions of all cultures
0	None	Discrete intracytoplasmic granules; no cell lysis
1	Slight	Not more than 20% of cells are round, loosely attached and without intracytoplasmic granules; occasional lysed cells are present
2	Mild	Not more than 50% of the cells are round and devoid of intracytoplasmic granules; extensive cell lysis and empty areas between cells
3	Moderate	No more than 70% of the cell layers contain rounded cells and/or are lysed
4	Severe	Nearly complete destruction of the cell layers

4.6 Cytotoxicity Results

The following table highlights the results obtained following two separate tests. Two or four readings were taken at each test. In all cases negative control (TCPS) provided a 0 grade.

Table 4

Material Code	Grade Test 1 L9292	Material Code	Grade Test 2 L929	Test 2 HUE
MATT01	0	MATT01	0	0
MATT02	-	MATT02	0	0
MATT03	-	MATT03	-	0
MATT04	0	MATT04	0	0
MATT05	0	MATT05	0	0

Comments

The results as detailed provide a very subjective assessment of material cytotoxicity. Where a grade 0 is shown, there was no evidence of toxicity and a confluent healthy monolayer of cells was present. Where there was evidence of contamination or where the cell monolayer is difficult to evaluate no score has been given.

4.7 Cell Substrate Results

The following table (Table 5) details the cell-fibre interactions and general cell culture conditions observed by phase contrast microscopy. As stated before phase-contrast images of the cells on the fibres are poor. A staining procedure was

carried out with the HUE cells. This procedure uses a fluorescent staining technique (ethidium bromide and acridene orange) to identify cell viability. All observations were after 48 hour contact between cells and fibres.

Table 5

	MATT01	MATT02	MATT03	MATT04	MATT05
L929 non-sterile fibres	Cells are viable.	Contamination	Contamination	Cells are viable. Healthy monolayer. There is some evidence of cell adhesion onto the fibres.	Cells are viable. Healthy monolayer. There is some evidence of cell adhesion onto the fibres.
L929 sterile fibres	Cells are viable but very granular. These fibres are having some adverse effect on the cells.	Culture medium pH levels are low. Cells are viable. There is no obvious cell adherence to the fibre.	pH is low. There seems to be evidence of contamination-though this may be degrading glass. Difficult to make any comment on cell viability.	Cells viable. Healthy monolayer. There is some evidence of cell adhesion onto the fibres.	Cells viable. Healthy monolayer. There is some evidence of cell adhesion onto the fibres.
HUE sterile fibres	Cells are viable though granular in appearance. The medium pH has dropped. Some cells can be seen adhering to the fibres (Figure 2).	Cells are viable. There is no obvious cell adherence to the fibre.	pH is low. There seems to be evidence of contamination-though this may be degrading glass. Difficult to make any comment on cell viability.	Cells viable. Cell monolayer on TCPS is healthy and equivalent to the control wells. There is some evidence of cell attachment but this is difficult to observe by phase contrast. (See Figure 3).	Cells viable. Cell monolayer on TCPS is healthy and equivalent to the control wells. There is some evidence of cell attachment but this is difficult to observe by phase contrast.

The images below were obtained following the vital staining procedure and examined by fluorescent microscopy.

As well as demonstrating cell viability the procedure permitted a better evaluation of the cells attaching to the fibres. The cell-fibre interaction was much better than that indicated by phase contrast microscopy. It was noted that

MATT04 and MATT05 had excellent cell adherence. MATT01 permitted a good cell adherence. There was cell attachment with MATT02 and MATT03 although this was poor in comparison with 01, 04 and 05.

Example 3

A cell suspension (in complete cell culture medium supplemented with 5% foetal calf serum) at a concentration of approx. 5 x 10^5 cell/ml was introduced to an established mouse fibroblast cell line (L929).

The material/cell interaction was examined using phase contrast microscopy at 24, 48 and 72 hours. In particular the following materials were examined (see Table 6 for composition of the glasses referred to by batch number).

a) Glass sheet (flat); code 1051098-1

Cells can be seen adhering to the material and remain in contact with the material following sequential transfer between dishes. The cell morphology is rounded and the growth rate is considerably slower than observed with cells on the control dishes. Nevertheless there is evidence of cell division taking place on the surface.

b) Sintered glass beads (smooth surface); code BX-D221098-1, Sintered glass beads (rough surface); code BX-D221098-1

It is more difficult to make the observations with these samples using phase contrast. However, cells are clearly present on the surface of both rough and smooth samples. The cell population is certainly increasing with time up to the 72 hour period. Again, this is following sequential transfer at 24 hours.

Table 6

Batch Number	Formulation as mole%			TOTAL	Solution Rates		Physical Form
	Na_2O	CaO	P_2O_5		Annealed @37.5°c (mg.cm'2.hr'1	Annealed @37.5°c (mg.cm'2.hr'1	
I051098-1	25	28	47	100	0.0991	0.1364	R+S
D221098-1	11	42	47	100	0.0377	0.0446	G+R

G=GRANULES R=RODS S=SHEETS

Sample SEMs were obtained (see Figs. 4 to 7) after cells had been in contact with the glass for 72 hours, fixed in 2.5% glutaraldehyde and dehydrated with alcohol. The samples were gold coated before viewing. The magnification is indicated on Figs. 4 to 7.

Figure 1

Figure 2



FIGURE 1 [MATT01]
The bright areas represent viable cells [HUE]. The image shows an area with bundles of fibres radiating in many directions. In most cases the cells are rounded and not elongated on the fibres.

Figure 3

FIGURE 2 [MATT04]
The bright areas represent viable cells [HUE]. Cells can be seen elongated on the fibres. In this image most of the fibres are oriented in the same direction. There is excellent cell coverage. This image is also representative of the result obtained with MATT05

Comment
Of the five fibre compositions examined MATT04 and MATT05 are providing an excellent substrate for cell adhesion. MATT01 has large numbers of cells adhering although the cell morphology is more rounded than that seen on the control surface. MATT02 and MATT03 show cells adhering but in much reduced numbers. There is no evidence of cytotoxicity with any of the fibres examined.

Figure 4



Figure 5



Figure 6



Figure 7



PCT NO: GB00/03424

Phil Treen.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.